Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report
Introduction: Vaginal cancer is a rare yet aggressive cancer, with unmet need for novel therapeutics. Case Presentation: In this case report, we present a patient with advanced stage, HPV-positive vaginal cancer who demonstrated clinical, radiological, and molecular response to combinatio...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-03-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000545141 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Vaginal cancer is a rare yet aggressive cancer, with unmet need for novel therapeutics. Case Presentation: In this case report, we present a patient with advanced stage, HPV-positive vaginal cancer who demonstrated clinical, radiological, and molecular response to combination treatment of antibody-drug conjugate enfortumab vedotin (EV) with pembrolizumab. Conclusion: This is the first reported response to this combination therapy in vaginal cancer in the literature. The patient had positive Nectin-4 staining on evaluation, raising the possibility for future clinical application of EV in vaginal squamous cell cancer. |
|---|---|
| ISSN: | 1662-6575 |